QIAGEN Buys Enzymatics
QIAGEN stated that it will support the universal product offerings of the Enzyme Solutions Unit. The Unit supplies companies such as Illumina and Life Technologies. According to QIAGEN, more than 80% of NGS reactions utilize Enzymatics reagents. At the JP Morgan Healthcare Conference, QIAGEN commented that the acquisition provides it with access to best-in-class enzymology “to drive the cost and performance curves of its GeneReader sequencer” after it is launched. The system is scheduled to be introduced in the second half of the year.
Hilden, Germany and Beverly, MA 1/11/15—QIAGEN has acquired Enzymatics’ Enzyme Solutions Unit for an undisclosed amount. The Unit develops, manufactures and is an OEM supplier of enzymes for genetic-analysis technologies, including NGS. The acquisition is expected to add $20 million of incremental net sales in 2015 and be accretive by $0.01 to adjusted diluted EPS. “Enzymatics has distinguished itself as a premier enabler of the emergence of affordable, widely usable NGS sequencing,” stated QIAGEN CEO Peer M. Schatz. “These solutions are a perfect fit with our leading offering of universal NGS products as well as with our strategy to develop integrated workflows that will help to drive the adoption of NGS in clinical healthcare.” Enzymatics’ ArcherDX business, which provides AMP chemistry for target enrichment, and its Supply Chain Solutions business have been spun off as a separate company, ArcherDX. QIAGEN has entered into a strategic partnership with ArcherDX for technology and distribution of unique NGS products. QIAGEN also announced that, for the fourth quarter 2014, it will take a $21 million business-integration and pretax charge on operating income (approximately $0.06 per share of adjusted diluted EPS) and a $26 million (approximately $0.08 per share) restructuring-related pretax charge on operating income.
